William E. Luginbuhl, MD profile ...

Dr. William E. Luginbuhl

Claim this profile

Chester County Hospital

Studies Ovarian Cancer
Studies Breast Cancer
14 reported clinical trials
50 drugs studied

Area of expertise

1

Ovarian Cancer

William E. Luginbuhl has run 5 trials for Ovarian Cancer. Some of their research focus areas include:

Stage II
Stage III
Stage IV
2

Breast Cancer

William E. Luginbuhl has run 4 trials for Breast Cancer. Some of their research focus areas include:

HER2 positive
ER negative
HER2 negative

Affiliated Hospitals

Image of trial facility.

Chester County Hospital

Clinical Trials William E. Luginbuhl is currently running

Image of trial facility.

Apalutamide + Hormone and Radiation Therapies

for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.

Recruiting

2 awards

Phase 3

Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Recruiting

1 award

Phase 2 & 3

13 criteria

More about William E. Luginbuhl

Clinical Trial Related

6 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments William E. Luginbuhl has experience with

  • Bevacizumab
  • Carboplatin
  • Paclitaxel
  • Letrozole
  • Paclitaxel, Carboplatin
  • Irinotecan

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does William E. Luginbuhl specialize in?

Is William E. Luginbuhl currently recruiting for clinical trials?

Are there any treatments that William E. Luginbuhl has studied deeply?

What is the best way to schedule an appointment with William E. Luginbuhl?

What is the office address of William E. Luginbuhl?

Is there any support for travel costs?